Metastasis from Malignant Tumor of Cervix clinical trials at UCSF
1 research study open to eligible people
When cervical cancer metastasizes, it means the cancer cells have moved to other areas in the body. UCSF conducts trials to assess the effects of NBTXR3 activated by radiotherapy on such advanced cancers. These trials also explore the benefit of combining this approach with anti-PD-1 therapy.
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Our lead scientists for Metastasis from Malignant Tumor of Cervix research studies include Jason Chan.
Last updated: